Cardiovascular collaboration

Tuesday, 10 May, 2005

Cryptome Pharmaceuticals has signed a memorandum of understanding with the University of Queensland's Institute for Molecular Biosciences (IMB) to collaborate on the identification of potential therapeutics for cardiovascular disease.

The IMB will provide Cryptome with high value compound libraries, which Cryptome will screen for potential activity using its proprietary Cryptomics platform technology. The Cryptomics drug discovery platform is based on finding small protein fragments with previously undiscovered therapeutic activities. These fragments are generated, screened and identified using the Cryptomics systematic high-throughput approach.

Related News

Australian Healthcare Week 2024: register for your free pass

With more than 150 leading health sector speakers, over 100 sessions and two deep-dive master...

Recommendations released: Pathway to Diversity in STEM Review

The Pathway to Diversity in STEM Review addresses the urgent need for Australia to boost its STEM...

Built for the future: KAESER Australia unveils new facility in Vic

The 4500 m2, $15 million facility features various innovations that echo KAESER's...


  • All content Copyright © 2024 Westwick-Farrow Pty Ltd